Generic Name and Formulations:
Potassium (as bicarbonate and citrate) 10mEq, 20mEq, 25mEq; effervescent tabs for soln; unflavored, cherry vanilla, orange cream, lemon citrus, cherry berry flavors.
Indications for EFFER-K:
Hypokalemia with or without metabolic alkalosis. Digitalis intoxication. Hypokalemic familial periodic paralysis. Prevention of potassium depletion when dietary intake is inadequate.
Take with food or immediately after a meal; sip slowly over 5–10 mins. 1 tab 1–4 times daily, based on patient requirement. Dissolve each 10mEq tab in 2–3oz of cold water or juice (if unflavored); dissolve each 20mEq tab in 3–4oz of cold water or juice (if unflavored); dissolve each 25mEq tab in 4oz of cold water or 12–16oz of cold juice (if unflavored).
Hyperkalemia. Chronic renal disease. Metabolic acidosis. Uncontrolled diabetes mellitus. Esophageal compression. Delayed gastric emptying. Intestinal obstruction/stricture. Peptic ulcer. Concomitant potassium-sparing diuretics (eg, spironolactone, triamterene).
Discontinue if GI bleed, ulceration, or other disturbances occur. Acidosis. Renal or cardiac disease. Monitor serum potassium and magnesium levels, renal function, clinical status, acid-base balance, and ECG. Elderly. Pregnancy (Cat.C). Nursing mothers.
Hyperkalemia with potassium-sparing diuretics, ACE inhibitors, NSAIDs, beta-adrenergic blockers, heparin, low-salt foods, potassium-containing drugs, digitalis glycosides, others.
Hyperkalemia, nausea, vomiting, abdominal discomfort, diarrhea.
Tabs 10mEq, 20mEq—30; 25mEq—30, 100 (orange-flavored)
Clinical Pain Advisor Articles
- Two Screening Tools May Accurately Predict Transition From Acute to Chronic Low Back Pain
- Tools to Address the Opioid Crisis
- Methamphetamine Use on the Rise in Patients With Opioid Use Disorder
- Operant Learning May Provide More Benefits Than Energy Conservation in Fibromyalgia
- Half of the Responders to Our Poll Agree With the Approval of Dsuvia: We Want to Hear From You
- The Unintended Consequences of the CDC Opioid Guideline According to Pain Management Specialists
- Initial Consultation for Neck Pain May Reduce Opioid Consumption, Healthcare Utilization
- FDA-Approved Test Provides Pharmacogenetic Reports Directly to Consumers
- Set of Interventions May Effectively Reduce Opioid Overprescribing
- Cannabinoid-Associated Analgesia May Be Mediated Through Modulation of Affective Processes
- FDA Panel Votes in Favor of Abuse-Deterrent Oxycodone Reformulation
- FDA Proposes New Restrictions on Sale of Electronic Nicotine Delivery Systems
- Central Sensitization in Greater Trochanteric Pain Syndrome
- Pain Acceptance May Reduce Headache-Related Disability in Migraine
- FDA Issues Safety Alert Regarding Intrathecal Delivery of Pain Meds